Triple chemotherapy combination improves metastatic colorectal cancer outcomes
Researchers from SWOG Cancer Research Network, a cancer clinical trials group funded by the National…
Browsing: encorafenib
FDA approves encorafenib in combination with cetuximab for metastatic colorectal cancer with a BRAF V600E mutation
The Food and Drug Administration (FDA) have approved encorafenib in combination with cetuximab for the…
Protected: PBS listing for BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) combination therapy for adults with unresectable malignant BRAF-mutant melanoma [1]
This content is password protected. To view it please enter your password below: Password: